Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

Simple item page
dc.contributor.authorRosa Polo
dc.contributor.authorXabier García‐Albéniz
dc.contributor.authorCarolina Terán
dc.contributor.authorMiguel Morales
dc.contributor.authorDavid Rial‐Crestelo
dc.contributor.authorMaría Ángeles Garcinuño
dc.contributor.authorMiguel García Deltoro
dc.contributor.authorCésar Hita
dc.contributor.authorJuan Luís Gómez-Sirvent
dc.contributor.authorLuís Buzón
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:17:33Z
dc.date.available2026-03-22T14:17:33Z
dc.date.issued2022
dc.descriptionCitaciones: 18
dc.identifier.doi10.1016/j.cmi.2022.07.006
dc.identifier.urihttps://doi.org/10.1016/j.cmi.2022.07.006
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/45660
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofClinical Microbiology and Infection
dc.sourceMinistry of Health
dc.subjectEmtricitabine
dc.subjectHydroxychloroquine
dc.subjectMedicine
dc.subjectPre-exposure prophylaxis
dc.subjectPlacebo
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectRandomized controlled trial
dc.subjectTenofovir
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subjectDouble blind
dc.titleDaily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers
dc.typearticle

Files

Collections

Artículo Científico Publicado